ESC Heart Failure (Feb 2025)

Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study

  • Giacomo Tini,
  • Beatrice Musumeci,
  • Paolo Milani,
  • Mattia Zampieri,
  • Angelo Giuseppe Caponetti,
  • Francesca Fabris,
  • Andrea Foli,
  • Alessia Argirò,
  • Carlotta Mazzoni,
  • Christian Gagliardi,
  • Simone Longhi,
  • Giulia Saturi,
  • Giuseppe Vergaro,
  • Alberto Aimo,
  • Ludovica De Fazio,
  • Guerino Giuseppe Varrà,
  • Matteo Serenelli,
  • Gioele Fabbri,
  • Laura De Michieli,
  • Giuseppe Palmiero,
  • Giuseppe Ciliberti,
  • Samuela Carigi,
  • Margherita Zanoletti,
  • Giulia Elena Mandoli,
  • Giulia Ricci Lucchi,
  • Valeria Rella,
  • Enrico Monti,
  • Elisa Gardini,
  • Michela Bartolotti,
  • Lia Crotti,
  • Elisa Merli,
  • Roberta Mussinelli,
  • Pier Filippo Vianello,
  • Matteo Cameli,
  • Francesca Marzo,
  • Federico Guerra,
  • Giuseppe Limongelli,
  • Alberto Cipriani,
  • Stefano Perlini,
  • Laura Obici,
  • Federico Perfetto,
  • Emanuele Barbato,
  • Italo Porto,
  • Gianfranco Sinagra,
  • Marco Merlo,
  • Michele Emdin,
  • Elena Biagini,
  • Francesco Cappelli,
  • Giovanni Palladini,
  • Marco Canepa

DOI
https://doi.org/10.1002/ehf2.15091
Journal volume & issue
Vol. 12, no. 1
pp. 379 – 388

Abstract

Read online

Abstract Aims Disease staging and prognostic scoring in wild‐type transthyretin‐related cardiac amyloidosis (ATTRwt‐CA) can be captured by two systems (NAC and Columbia scores). However, uncertainty remains as epidemiology of the disease is evolving rapidly. We evaluated features associated with staging systems across ATTRwt‐CA patients from different diagnostic pathways, and their association with prognosis. Methods We performed an analysis on DIAMOND patients with available data to evaluate NAC and Columbia score. DIAMOND was a retrospective study from 17 Italian referral centres for CA, enrolling 1281 patients diagnosed between 2016 and 2021, and aimed at describing characteristics of pathways leading to ATTRwt‐CA diagnosis. Of the original cohort, 811 patients were included in this analysis. Each patient had NAC and Columbia score calculated. Patients were grouped according to NAC and Columbia scoring classes. We described characteristics of patients according to staging classes and diagnostic pathways at diagnosis. Prevalence of early diagnoses, defined as NAC Ia, NYHA class I, no use of diuretics, no history of heart failure (HF) hospitalizations nor of atrial fibrillation prior to diagnosis, was investigated. Finally, prognostic variables were tested alone and grouped as NAC or Columbia scores in Cox univariate and multivariate regression analyses. Prognosis was investigated as all‐cause mortality, in the whole population and dividing patients in HF versus other diagnostic pathways. Results Only 1% of the study population had an early ATTRwt‐CA diagnosis. Distribution of prognostic variables and of NAC and Columbia classes was heterogeneous across diagnostic pathways. The prevalence of NAC III and Columbia III was higher in the HF diagnostic pathway, but all NAC and Columbia classes were present in all pathways. Both NAC and Columbia scores were associated with all‐cause mortality at univariate Cox regression analysis in the whole population, in patients from the HF diagnostic pathway and in those from other pathways. At multivariate analysis, Columbia score remained significantly associated with the outcome, together with age at diagnosis, left ventricular ejection fraction and maximal wall thickness. Conclusions In this contemporary nationwide cohort, an ATTRwt‐CA early diagnosis was very rare. Disease staging with NAC and Columbia scoring systems determined classes of patients with heterogeneous features. Both scores were significantly associated with mortality, but other variables also had prognostic significance.

Keywords